Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc.

Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families.  Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development.

Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.

Biomatics Capital Partners

Alaska Permanent Fund

ARCH Venture Partners

Flagship Pioneering

Baillie Gifford

F-Prime Capital

Eight Roads Ventures

Denali Therapeutics

The #bloodbrainbarrier protects the brain from toxins, but also prevents medicines from entering the brain. We’ve invented a Transport Vehicle (TV) designed to enable protein-based medicines to be carried across that barrier and delivered throughout the brain via existing biological pathways. This novel brain delivery technology has the potential to address a variety of diseases that cause damage inside the brain, potentially making further medical advancements possible. 
#DefeatDegeneration #BrainAwarenessWeek 

We reported our Q3 financial results and business highlights. Read our press release: https://lnkd.in/gubA5Ck2

#TeamDenali joined the Alzheimer's Association of Northern California & Northern Nevada for the Walk to End Alzheimer's in San Francisco this past weekend. Together with the local community, we've taken steps to increase awareness and support research. Thank you to all who participated in this inspiring annual event!   #Walk2EndAlz #AlzheimersAwareness 
#defeatdegeneration

Over the weekend, Denali team members participated in Project Alive's inaugural Hunter syndrome Family Fair, enjoying a day filled with education, connection and Halloween-themed activities with more than 30 MPS II families from across the country! We extend our gratitude to Project Alive for inviting Denali to be a part of this event and value the opportunity to connect with the community and partake in the festive trick-or-treating fun. 

Our team was delighted to participate in the 37th Annual Family and Scientific Conference organized by the National MPS Society in Bethesda, MD. It was another impactful gathering, uniting a diverse community dedicated to having a positive impact in the lives of individuals with MPS and their families. We are grateful for the collaboration and the chance to highlight Denali's research contributions and efforts to develop potential new treatments in MPS. #MPSFamily2023 #defeatdegeneration 

	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue				129.16M -	26.68M 79.34%	335.66M 1,158.19%	48.66M 85.50%	108.46M 122.90%	330.53M 204.74%
cost of revenue									16.73M -
gross profit				129.16M -	26.68M 79.34%	335.66M 1,158.19%	48.66M 85.50%	108.46M 122.90%	313.81M 189.32%
selling and marketing expenses									-16.73M -
general and administrative expenses	5.11M -	11.73M 129.66%	15.68M 33.66%	32.35M 106.31%	46.48M 43.68%	60.33M 29.79%	79.06M 31.05%	90.47M 14.44%	103.35M 14.23%
selling general and administrative expenses	5.11M -	11.73M 129.66%	15.68M 33.66%	32.35M 106.31%	46.48M 43.68%	60.33M 29.79%	79.06M 31.05%	90.47M 14.44%	86.63M 4.25%
research and development expenses	11.57M -	75.70M 554.24%	74.46M 1.64%	143.18M 92.30%	193.38M 35.06%	212.62M 9.95%	265.35M 24.80%	358.73M 35.19%	423.88M 18.16%
other expenses
cost and expenses	16.68M -	87.43M 424.21%	90.14M 3.10%	175.53M 94.73%	239.86M 36.65%	272.94M 13.79%	344.41M 26.19%	449.21M 30.43%	527.23M 17.37%
operating expenses	16.68M -	87.43M 424.21%	90.14M 3.10%	175.53M 94.73%	239.86M 36.65%	272.94M 13.79%	344.41M 26.19%	449.21M 30.43%	510.50M 13.65%
interest expense			1.96M -		15.22M -			14.77M -
ebitda	-16.56M -	-85.96M 419.17%	-90.14M 4.86%	-46.37M 48.56%	-213.18M 359.73%	62.72M 129.42%	-295.75M 571.56%	-330.36M 11.70%	-179.97M 45.52%
operating income	-16.68M -	-87.43M 424.21%	-90.14M 3.10%	-46.37M 48.56%	-213.18M 359.73%	62.72M 129.42%	-295.75M 571.56%	-340.74M 15.21%	-196.70M 42.27%
depreciation and amortization	121K -	1.47M 1,114.05%	3.08M 109.80%	7.42M 140.59%	7.99M 7.77%	8.53M 6.76%	8.59M 0.73%	10.38M 20.83%	16.73M 61.09%
total other income expenses net	-109K -	781K 816.51%	1.96M 150.32%	10.13M 418.26%	15.22M 50.21%	9.24M 39.28%	4.59M 50.28%	14.77M 221.52%	51.51M 248.62%
income before tax	-16.79M -	-86.65M 416.15%	-88.19M 1.77%	-36.24M 58.90%	-197.97M 446.26%	71.96M 136.35%	-291.16M 504.61%	-325.97M 11.96%	-145.19M 55.46%
income tax expense			-3.08M -	10.13M 428.75%	-351K 103.46%	823K 334.47%	-575K 169.87%	21K 103.65%	30K 42.86%
net income	-16.79M -	-86.65M 416.15%	-88.19M 1.77%	-36.24M 58.90%	-197.61M 445.29%	71.14M 136.00%	-290.58M 508.49%	-325.99M 12.19%	-145.22M 55.45%
weighted average shs out	3.01M -	6.42M 113.70%	14.96M 132.92%	92.62M 518.96%	95.61M 3.22%	108.97M 13.98%	121.52M 11.52%	125.53M 3.30%	137.37M 9.43%
weighted average shs out dil	3.01M -	6.42M 113.70%	14.96M 132.92%	92.62M 518.96%	95.61M 3.22%	112.70M 17.88%	121.52M 7.83%	125.53M 3.30%	137.37M 9.43%
eps	-5.58 -	-13.49 141.76%	-5.89 56.34%	-0.39 93.38%	-2.07 430.77%	0.65 131.40%	-2.39 467.69%	-2.60 8.79%	-1.06 59.23%
epsdiluted	-5.58 -	-13.49 141.76%	-5.89 56.34%	-0.39 93.38%	-2.07 430.77%	0.63 130.43%	-2.39 479.37%	-2.60 8.79%	-1.06 59.23%

COM:DENALITHERAPEUTICS

Denali Therapeutics Inc

Last Close

24.42

21/11 21:00

Market Cap

3.09B

Beta: -

Volume Today

1.46M

Avg: -

Preview